Contineum Therapeutics (CTNM) PT Raised to $23 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CTNM Hot Sheet
Price: $9.79 +1.03%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung raised the price target on Contineum Therapeutics (NASDAQ: CTNM) to $23.00 (from $21.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Contineum Therapeutics (CTNM) PT Lowered to $23 at Stifel
- ArcBest Corp (ARCB) PT Lowered to $146 at TD Cowen
- Avis Budget Group (CAR) PT Lowered to $125 at Susquehanna
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
